Literature DB >> 23909747

The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative.

Marco Aurélio P Sáfadi1, Luz Elena Espinosa de los Monteros, Eduardo Luis López, Xavier Sàez-Llorens, Ana Paula Lemos, Sarbelio Moreno-Espinosa, Silvia González Ayala, Juan Pablo Torres, José Cassio de Moraes, Julio Alberto Vázquez.   

Abstract

The Global Meningococcal Initiative (GMI) is an international group of scientists and clinicians with expertise in meningococcal disease (MD). It promotes MD prevention through education and research. Given geographic differences in disease epidemiology, prevention strategies (e.g., vaccination) should be country-specific to ensure local needs are met. However, regional policies/recommendations and standardized disease diagnostic criteria should be implemented to improve surveillance and control strategies, and allow for more robust data comparisons. Consequently, the GMI convened a meeting with Latin American representatives to discuss the burden of MD and vaccination practices/policies, and consider if the global GMI recommendations could be tailored. The group determined that as robust, uniform epidemiologic data are required to make informed health-policy decisions, it would be useful to first summarize the regional situation herein (including disease surveillance, case definitions, epidemiology, vaccination and outbreak control strategies) and then determine a consensus-based meningococcal case definition for use throughout the region.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23909747     DOI: 10.1586/14760584.2013.814879

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  11 in total

Review 1.  Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.

Authors:  Rodolfo Villena; Marco Aurelio P Safadi; María Teresa Valenzuela; Juan P Torres; Adam Finn; Miguel O'Ryan
Journal:  Hum Vaccin Immunother       Date:  2018-04-30       Impact factor: 3.452

Review 2.  Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection.

Authors:  E David McIntosh; Victor Carey; Daniela Toneatto; Peter Dull; James Wassil
Journal:  Ther Adv Vaccines       Date:  2015-01

Review 3.  Challenges and opportunities for meningococcal vaccination in the developing world.

Authors:  Rouba Shaker; Danielle Fayad; Ghassan Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2018-02-23       Impact factor: 3.452

Review 4.  A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.

Authors:  Miguel O'Ryan; Jeffrey Stoddard; Daniela Toneatto; James Wassil; Peter M Dull
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

5.  Economic Impact of Meningococcal Outbreaks in Brazil and Colombia.

Authors:  D Constenla; A Carvalho; N Alvis Guzmán
Journal:  Open Forum Infect Dis       Date:  2015-11-12       Impact factor: 3.835

Review 6.  Global Meningococcal Initiative: guidelines for diagnosis and confirmation of invasive meningococcal disease.

Authors:  J A Vázquez; M K Taha; J Findlow; S Gupta; R Borrow
Journal:  Epidemiol Infect       Date:  2016-06-30       Impact factor: 2.451

7.  Molecular characterization of Neisseria meningitidis isolates recovered from 11-19-year-old meningococcal carriers in Salvador, Brazil.

Authors:  Ana Rafaela Silva Simões Moura; Cécilia Batmalle Kretz; Italo Eustáquio Ferreira; Amélia Maria Pithon Borges Nunes; José Cássio de Moraes; Mitermayer Galvão Reis; Alan John Alexander McBride; Xin Wang; Leila Carvalho Campos
Journal:  PLoS One       Date:  2017-09-20       Impact factor: 3.240

8.  Estimation of the real burden of invasive meningococcal disease in Argentina.

Authors:  J A Gómez; P Wetzler Malbrán; G Vidal; M Seoane; N D Giglio
Journal:  Epidemiol Infect       Date:  2019-11-29       Impact factor: 2.451

9.  Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults.

Authors:  Xavier Sáez-Llorens; Johnny Beltran-Rodriguez; Jose M Novoa Pizarro; Ilhem Mensi; Pavitra Keshavan; Daniela Toneatto
Journal:  Hum Vaccin Immunother       Date:  2018-05-09       Impact factor: 3.452

10.  A critical analysis of serogroup B meningococcal disease burden in Brazil (2001-2015): implications for public health decisions.

Authors:  Luciana Andrea Digieri Chicuto; Camile de Moraes; José Cássio de Moraes; Marco Aurélio P Sáfadi
Journal:  Hum Vaccin Immunother       Date:  2020-01-17       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.